AP NEWS

China Pancreatic Kininogenase Market Report 2018: Concepts, Sales (2013-2017), Manufacturers (2013-2017), Prices (2017-2018) & Prospects (2018-2022) - ResearchAndMarkets.com

January 8, 2019

DUBLIN--(BUSINESS WIRE)--Jan 8, 2019--The “Investigation Report on China’s Pancreatic Kininogenase Market, 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

Pancreatic Kininogenase can be used to treat cardiovascular and cerebrovascular diseases such as primary hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal vascular disorder and peripheral vascular disease.

Recent studies have found that Pancreatic Kininogenase can also be used to prevent diabetic microangiopathy and early diabetic nephropathy by reducing the discharge of urinary albumin. In addition, Pancreatic Kininogenase can increase the activity and production of sperms, and thus has a certain curative effect on male infertility, according to domestic clinical data.

In 1999, Changzhou Qianhong Bio-pharma Co., Ltd.‘s Pancreatic Kininogenase was first launched in China, followed by the counterparts of Chengdu Tongde Pharmaceutical Co., Ltd., Henan Livu Pharmacy Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., etc. At present, there are seven Pancreatic Kininogenase manufacturers in China. Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase (trade name: Yikai) takes up about 90% market share by sales value.

It is expected that as the incidence of cardiovascular and cerebrovascular diseases continues to increase, China’s Pancreatic Kininogenase market will still have some growth potential in the next few years.

Key Topics Covered:

1 Relevant Concepts of Pancreatic Kininogenase

2 Sales of Pancreatic Kininogenase in China, 2013-2017

3 Analysis of Major Pancreatic Kininogenase Manufacturers in China, 2013-2017

4 Prices of Pancreatic Kininogenase in China, 2017-2018

5 Prospect of China’s Pancreatic Kininogenase Market, 2018-2022

Companies Mentioned

Changzhou Qianhong Bio-pharma Co., Ltd. (Yikai) Chengdu Tongde Pharmaceutical Co., Ltd. (Tongde) Henan Livu Pharmaceutical Co., Ltd. (Duomeile) Shanghai Livzon Pharmaceutical Co., Ltd. (Guangle) Sichuan Shunsheng Pharmaceutical Co., Ltd. (Dashun)

For more information about this report visit https://www.researchandmarkets.com/research/cvpttr/china_pancreatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190108005498/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH OTHER HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/08/2019 06:17 AM/DISC: 01/08/2019 06:17 AM

http://www.businesswire.com/news/home/20190108005498/en

AP RADIO
Update hourly